Abstract
2125 Background: The anthracyclines are among the most useful agents in the treatment of solid malignancies and exhibit a wide range of antitumor activity. Adriamycin is most commonly used, but therapy is associated with significant bone marrow and organ toxicities. Therefore, an albumin-binding prodrug of adriamycin with acid-sensitive properties, i.e. (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), was developed that binds to circulating albumin with high affinity after intravenous application in a first step thus preventing rapid diffusion of adriamycin into healthy tissue. Due to a passive accumulation of albumin in solid tumors, DOXO-EMCH is targeted to the tumor and releases adriamycin in the acidic environment of tumor tissue. DOXO-EMCH has shown superior antitumor efficacy and an improved toxicity profile in various animal models compared to adriamycin. The objectives of this phase I trial is to evaluate the safety profile and pharmacokinetics of DOXO-EMCH in order to assess t...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call